Madrigal Pharmaceuticals

MDGLNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$12.059 B

$521.96 -1.80%

Close of 21 Sept 2026

Revenue

$180.1M

#2320 by revenue

Earnings

-$288.3M

Loss-making

Shares outstanding

23,104,126

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#29Biomarin PharmaceuticalBMRN$12.4B
#30Corcept TherapeuticsCORT$12.3B
#31Madrigal PharmaceuticalsMDGL$12.1B
#32Elanco Animal HealthELAN$11.2B
#33Axsome TherapeuticsAXSM$10.8B

What if Madrigal Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$1,310,331

Per share 2,510× higher

Bitcoin $1.72T

$74,437.08

Per share 143× higher

Nvidia $5.48T

$237,180.93

Per share 454× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Madrigal Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.